By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
PHARMA JOBS POSTPHARMA JOBS POSTPHARMA JOBS POST
  • HOME
  • FRESHERS
  • LOCATIONS
  • ABOUT US
  • CONTACT
  • DISCLAIMER
Notification
PHARMA JOBS POSTPHARMA JOBS POST
  • HOME
  • FRESHERS
  • LOCATIONS
  • ABOUT US
  • CONTACT
  • DISCLAIMER
Have an existing account? Sign In
Follow US
PHARMA JOBS POST © 2024 All Rights Reserved.
WhatsApp Group Join Now
Telegram Group Join Now
- Advertisement -
Ad imageAd image
Ad imageAd image
PHARMA JOBS POST > announcement > FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
announcementColorectal cancer

FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

RAJLAXMI
Last updated: May 8, 2025 6:21 pm
RAJLAXMI 21 minutes ago
Share
SHARE

The Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.

Full prescribing information for Opdivo and Yervoy will be posted on Drugs@FDA.

Efficacy and Safety;

Efficacy of nivolumab with ipilimumab was evaluated in CHECKMATE-8HW (NCT04008030), a randomized, three-arm, open-label trial in immunotherapy-naïve patients with unresectable or metastatic CRC with known MSI-H or dMMR status. Patients were randomized to receive one of the following treatments:

• nivolumab 240 mg every 3 weeks and ipilimumab 1 mg/kg every 3 weeks for a maximum of 4 doses, then nivolumab 480 mg every 4 weeks,

• nivolumab 240 mg every 2 weeks for 6 doses, then nivolumab 480 mg every 4 weeks, or
investigator’s choice chemotherapy:

The major efficacy outcome measure was progression-free survival (PFS) assessed by blinded independent central review (BICR) per RECIST v1.1 in patients with centrally confirmed MSI-H/dMMR status in the following pre-specified settings:

First-line setting: nivolumab + ipilimumab versus chemotherapy,
All lines: nivolumab + ipilimumab versus nivolumab alone.
The analysis of nivolumab + ipilimumab versus chemotherapy in the first line setting was conducted in 255 patients with centrally confirmed MSI-H/dMMR status of 303 patients based on local testing. Median PFS was not reached (NR) (95% CI: 38.4, not estimable [NE]) in the nivolumab + ipilimumab arm and 5.8 months (95% CI: 4.4, 7.8) in the chemotherapy arm (Hazard ratio 0.21 [95% CI: 0.14, 0.32] p-value <0.0001). Comparative results of ORR and OS between arms were not available at the time of the interim PFS analysis due to statistical testing strategy.

• First-line setting: nivolumab + ipilimumab versus chemotherapy,

• All lines: nivolumab + ipilimumab versus nivolumab alone.

The analysis of nivolumab + ipilimumab versus chemotherapy in the first line setting was conducted in 255 patients with centrally confirmed MSI-H/dMMR status of 303 patients based on local testing. Median PFS was not reached (NR) (95% CI: 38.4, not estimable [NE]) in the nivolumab + ipilimumab arm and 5.8 months (95% CI: 4.4, 7.8) in the chemotherapy arm (Hazard ratio 0.21 [95% CI: 0.14, 0.32] p-value <0.0001). Comparative results of ORR and OS between arms were not available at the time of the interim PFS analysis due to statistical testing strategy.

The analysis of nivolumab + ipilimumab versus nivolumab (all lines) was conducted in 582 patients with centrally confirmed MSI-H/dMMR status of 707 patients based on local testing. Median PFS was NR (95% CI: 53.8, NE) in the nivolumab + ipilimumab arm and 39.3 months (95% CI: 22.1, NE) in the nivolumab arm (Hazard ratio 0.62 [95% CI: 0.48, 0.81] p-value 0.0003). ORR was 71% (95% CI: 65, 76) in the nivolumab + ipilimumab arm and 58% (95% CI: 52, 63) in the nivolumab arm (p-value 0.0011). The comparative results of OS between arms were not available at the interim PFS analysis due to statistical testing strategy.

The most common adverse reactions reported in ≥20% of patients treated with nivolumab with ipilimumab were fatigue, diarrhea, pruritus, abdominal pain, musculoskeletal pain, and nausea. The most common adverse reactions reported in ≥20% of patients treated with nivolumab as a single agent were fatigue, diarrhea, abdominal pain, pruritis, and musculoskeletal pain.

WhatsApp Group Join Now
Telegram Group Join Now
- Advertisement -
DEFINE ACADEMY DRUG REGULATORY AFFAIRSDEFINE ACADEMY DRUG REGULATORY AFFAIRS
TAGGED: FDA, treatment
Share This Article
Facebook Twitter LinkedIn Email Print
Previous Article Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECENT POSTS

  • FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
  • Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
  • FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities
  • Vital Therapeutics Freshers & Experts walk in for RO/DM Plant Operators, & Production Chemists | 10th May
  • IDRS Labs Walk-In Interview for Analytical Development – 10 May 2025
  • Zydus Hiring Freshers | Production, Engineering & Packing Jobs 2025
  • Walk-In Drive at Marksans Pharma on 11th May 2025 – Multiple Openings
  • Ciron Drugs Freshers Hiring alert 2025 | QC Microbiology Jobs
  • Aspiro Pharma Walk-In Interview for QA Positions – May 9, 2025
  • Innoxel Lifesciences Walk-In Drive for Pharma Professionals on May 11, 2025
  • Micro Labs Ltd Walk-in Interview on May 10, 2025   for Production, QA, Packing & Engineering Roles – Freshers & Experienced Candidates Welcome
  • Ajanta Pharma Walk-In Interview on May 11, 2025 – Manufacturing, Packing & QC Jobs
  • Gland Pharma Walk-In Interview for Production – May 9, 2025 | Apply Now
JOIN WHATSAPP CHANNEL

Recent Jobs

  • IQVIA

    IQVIA Hiring Safety Associate Trainee – Kickstart Your Career in Pharmacovigilance!

    • Kolkata, India
    • IQVIA
  • Maithri Drugs Private Limited

    Maithri Drugs Private Limited Hiring Trainee Executives – Quality Control, 0–4 Years Experience

    • Sangareddy (D), Telangana
    • Maithri Drugs Private Limited
  • Cadila Pharmaceuticals Limited

    Hiring Alert: Cadila Pharmaceuticals Recruiting for OSD & Injectable Production

    • Ahmedabad, Gujarat
    • Cadila Pharmaceuticals Limited
  • Morepen Laboratories Ltd.

    Career Opportunity for M.Sc. / M.Pharma Freshers in Regulatory Affairs at Morepen Laboratories Ltd.

    • Parwanoo (HP)
    • Morepen Laboratories Ltd.
  • Ortiv-Q3

    Ortiv-Q3 Announces Exciting Job Openings for Freshers & Exp in HR, R&D, and Analytical Sciences

    • Ahmedabad
    • Ortiv-Q3
  • Emcure Pharmaceuticals Ltd.

    Walk-In Interview at Emcure OSD Plant – Production (OSD)/ QA/ QC/ Engineering/ Warehouse/ IT – CSV on Friday, 09 May 2025

    • Surendranagar, Gujarat
    • Emcure Pharmaceuticals Ltd.
  • Clearsynth

    Clearsynth Invites B.Pharm / M.Sc Fresh Talent for Market Research Role in Mumbai

    • Mumbai
    • Clearsynth
  • Virchow Biotech Pvt. Ltd.

    Virchow Biotech Pvt. Ltd. is Hiring Freshers for Quality Control Roles

    • Hyderabad, Telangana
    • Virchow Biotech Pvt. Ltd.
  • Macleods Pharmaceuticals Ltd.

    Macleods Pharmaceuticals Ltd. Announces Walk-in Drive for Freshers on 12th May 2025

    • Sarigam, Valsad, Gujarat
    • Macleods Pharmaceuticals Ltd.
  • Axio Biosolutions

    0–3 Years Experience? Step Into the World of Clinical Affairs with Axio Biosolutions

    • Ahmedabad
    • Axio Biosolutions
  • Tata 1mg

    Hiring Pharmacists in Hyderabad | 0–5 Yrs Exp | ₹3–5 LPA | Tata 1mg

    • Hyderabad
    • Tata 1mg
  • Eris Bionxt Pvt Ltd

    Job Opportunities at Eris Bionxt – QA, QC, Microbiology & Engineering Roles

    • Mandideep, Bhopal, Madhya Pradesh
    • Eris Bionxt Pvt Ltd

Tags

Ahmedabad (65) ahmedabad pharma jobs (189) ahmedabad pharma vacancy (165) ahmedabad pharma walk in interview (89) Baddi Pharma Vacancy (59) Bangalore pharma company jobs (41) Bangalore pharma jobs (31) FRESHERS (181) freshers jobs in pharma industry (50) freshers pharmacy jobs (46) goa pharma company job (27) Hiring (119) Hiring jobs (428) Hyderabad (57) hyderabad pharma company jobs (183) hyderabad pharma jobs (94) hyderabad pharma jobs freshers (42) hyderabad pharma vacancies (111) hyd pharma jobs (31) indore pharma company vacancy (27) job alert (349) job Opportunity (246) Job search (427) job Vaccancy (419) Mumbai Pharma company jobs (34) Pharmacovigilance Jobs vacancy (38) Pharma jobs (104) Pharma jobs at Baddi (36) pharma jobs in hyderabad (84) Pharma QA Jobs (35) pharma qa vacancy (28) pharma vacancy in ahmedabad (30) pharma walk in interview (44) Production (58) Production Department (73) QA (53) QC (76) QC Department (45) Quality Control (QC) (31) Regulatory Affairs (55) Regulatory Affairs Jobs Vacancy (63) Vadodara (33) Vadodara Pharma Job Vacancy (53) Walk In Drive (125) Walk In Interview (180)
PHARMA JOBS POSTPHARMA JOBS POST
Follow US
PHARMA JOBS POST © 2024 All Rights Reserved.
JOIN OUR WHATSAPP GROUP
JOIN OUR TELEGRAM GROUP
Welcome Back!

Sign in to your account

Lost your password?